This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clarke, L. Articles by Waxman, D. J. Search for Related Content PubMed PubMed Citation Articles by Clarke, L. Articles by Waxman, D. J.

Oxidative Metabolism of Cyclophosphamide: Identification of the Hepatic Monooxygenase Catalysts of Drug Activation¹

Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115

Cytochrome P-450-catalyzed activation of cyclophosphamide to alkylating metabolites was studied in isolated rat liver microsomes and purified, reconstituted P-450 enzyme systems in order to identify the major enzymatic catalysts of drug activation in both uninduced and drug-induced liver tissue. P-450 form PB-4 (P-450 gene IIB1) activated cyclophosphamide with high efficiency [V_max (app) = 18.2 nmol metabolite/min/nmol P-450; K_m (app) = 0.16 mM] via the formation of 4-hydroxycyclophosphamide, which was quantitatively trapped as a bisulfite adduct then characterized following its conversion to cyano derivatives. Antibodies to P-450 PB-4 inhibited cyclophosphamide activation catalyzed by phenobarbital-induced adult male rat liver microsomes (specific activity, 5.4 nmol metabolite/min/mg liver microsomes) in a selective and near quantitative (>80%) fashion; little or no inhibition was obtained using antibodies inhibitory towards six other rat hepatic P-450 forms. Cyclophosphamide activation catalyzed by uninduced adult male rat liver microsomes (specific activity, 0.68 nmol/min/mg), although not inhibited by anti-P-450 PB-4 antibodies, was partially inhibited (60%) by antibodies to P-450 PB-1 (gene IIC6) and more completely inhibited (>95%) by antibodies reactive with both P-450 PB-1 and P-450 2c (gene IIC11). Consistent with these observations, P-450 PB-1 and P-450 2c both activated cyclophosphamide at moderate rates in reconstituted systems (turnover, 1.6–2.7 nmol metabolite/min/nmol P-450), while seven other purified hepatic P-450 forms exhibited significantly lower activities (turnover 0.5 nmol metabolite/min/nmol P-450). Further studies revealed that the changes in liver microsomal cyclophosphamide activation rates with age and sex and in response to in vivo administration of cisplatin primarily reflect changes in the levels of P-450 forms PB-1 and 2c. These studies establish that P-450 forms PB-1, 2c, and PB-4 are the major catalysts of cyclophosphamide activation in rat hepatic tissue and that the modulation of microsomal cyclophosphamide activation with development and in response to drug exposure largely reflects alterations in the levels of these three hepatic P-450 enzymes.

¹ Supported in part by Grant BC-462 from the American Cancer Society (D. J. W.).

² To whom correspondence should be addressed, at Dana-Farber Cancer Institute, JF-525, 44 Binney Street, Boston, MA 02115.

Received 6/ 8/88. Revised 10/27/88. Revised 1/27/89. Accepted 2/ 2/89.

This article has been cited by other articles:

				Q.-Y. Zhang, L. S. Kaminsky, D. Dunbar, J. Zhang, and X. Ding Role of Small Intestinal Cytochromes P450 in the Bioavailability of Oral Nifedipine Drug Metab. Dispos., September 1, 2007; 35(9): 1617 - 1623. [Abstract] [Full Text] [PDF]

				J. Gu, C.-S. Chen, Y. Wei, C. Fang, F. Xie, K. Kannan, W. Yang, D. J. Waxman, and X. Ding A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 9 - 17. [Abstract] [Full Text] [PDF]

				G. J. Pass, D. Carrie, M. Boylan, S. Lorimore, E. Wright, B. Houston, C. J. Henderson, and C. R. Wolf Role of Hepatic Cytochrome P450s in the Pharmacokinetics and Toxicity of Cyclophosphamide: Studies with the Hepatic Cytochrome P450 Reductase Null Mouse Cancer Res., May 15, 2005; 65(10): 4211 - 4217. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, et al. Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma Clin. Cancer Res., February 15, 2005; 11(4): 1512 - 1520. [Abstract] [Full Text] [PDF]

				C. Thallinger, M. F. Wolschek, H. Maierhofer, H. Skvara, H. Pehamberger, B. P. Monia, B. Jansen, V. Wacheck, and E. Selzer Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma: Synergistic Inhibition of Human Sarcoma Xenotransplants by a Combination of Mcl-1 Antisense Oligonucleotides with Low-Dose Cyclophosphamide Clin. Cancer Res., June 15, 2004; 10(12): 4185 - 4191. [Abstract] [Full Text] [PDF]

				C.-S. Chen, J. T. Lin, K. A. Goss, Y.-a. He, J. R. Halpert, and D. J. Waxman Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics Mol. Pharmacol., May 1, 2004; 65(5): 1278 - 1285. [Abstract] [Full Text]

				J. T. Mullen and K. K. Tanabe Viral Oncolysis for Malignant Liver Tumors Ann. Surg. Oncol., July 1, 2003; 10(6): 596 - 605. [Abstract] [Full Text] [PDF]

				S. Hamada, K. Nakajima, T. Serikawa, and M. Hayashi The effect of aging on the results of the rat micronucleus assay Mutagenesis, May 1, 2003; 18(3): 273 - 275. [Abstract] [Full Text] [PDF]

				C. J. A. Ring Cytolytic viruses as potential anti-cancer agents J. Gen. Virol., March 1, 2002; 83(3): 491 - 502. [Abstract] [Full Text] [PDF]

				P. Y.P. Lam and X. O. Breakefield Potential of gene therapy for brain tumors Hum. Mol. Genet., April 1, 2001; 10(7): 777 - 787. [Abstract] [Full Text] [PDF]

				T. Ichikawa, W. P. Petros, S. M. Ludeman, J. Fangmeier, F. H. Hochberg, O. M. Colvin, and E. A. Chiocca Intraneoplastic Polymer-based Delivery of Cyclophosphamide for Intratumoral Bioconversion by a Replicating Oncolytic Viral Vector Cancer Res., February 1, 2001; 61(3): 864 - 868. [Abstract] [Full Text]

				T. M. Pawlik, H. Nakamura, S. S. Yoon, J. T. Mullen, S. Chandrasekhar, E. A. Chiocca, and K. K. Tanabe Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus Cancer Res., June 1, 2000; 60(11): 2790 - 2795. [Abstract] [Full Text] [PDF]

				M. Aghi, T. C. Chou, K. Suling, X. O. Breakefield, and E. A. Chiocca Multimodal Cancer Treatment Mediated by a Replicating Oncolytic Virus That Delivers the Oxazaphosphorine/Rat Cytochrome P450 2B1 and Ganciclovir/Herpes Simplex Virus Thymidine Kinase Gene Therapies Cancer Res., August 1, 1999; 59(16): 3861 - 3865. [Abstract] [Full Text] [PDF]

				P. Roy, L. J. Yu, C. L. Crespi, and D. J. Waxman Development of a Substrate-Activity Based Approach To Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles Drug Metab. Dispos., June 1, 1999; 27(6): 655 - 666. [Abstract] [Full Text]

				L. J. Yu, P. Drewes, K. Gustafsson, E. G. C. Brain, J. E. D. Hecht, and D. J. Waxman In Vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 928 - 937. [Abstract] [Full Text]

				E. L. Code, C. L. Crespi, B. W. Penman, F. J. Gonzalez, T. K. H. Chang, and D. J. Waxman Human Cytochrome P4502B6. Interindividual Hepatic Expression, Substrate Specificity, and Role in Procarcinogen Activation Drug Metab. Dispos., August 1, 1997; 25(8): 985 - 993. [Abstract] [Full Text]

				E. Kashiyama, T. Yokoi, M. Odomi, Y. Funae, K. Inoue, and T. Kamataki CYTOCHROME P450 RESPONSIBLE FOR THE STEREOSELECTIVE S-OXIDATION OF FLOSEQUINAN IN HEPATIC MICROSOMES FROM RATS AND HUMANS Drug Metab. Dispos., June 1, 1997; 25(6): 716 - 724. [Abstract] [Full Text]